Free Trial
NASDAQ:GILD

Gilead Sciences (GILD) Stock Price, News & Analysis

Gilead Sciences logo
$110.67 +3.05 (+2.83%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$110.85 +0.18 (+0.16%)
As of 05:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Gilead Sciences Stock (NASDAQ:GILD)

Key Stats

Today's Range
$106.84
$112.00
50-Day Range
$96.86
$113.00
52-Week Range
$66.01
$119.96
Volume
19.54 million shs
Average Volume
7.65 million shs
Market Capitalization
$137.67 billion
P/E Ratio
23.30
Dividend Yield
2.86%
Price Target
$110.55
Consensus Rating
Moderate Buy

Company Overview

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company headquartered in Foster City, California, that focuses on the discovery, development and commercialization of innovative medicines. Since its founding in 1987 by Dr. Michael L. Riordan, Gilead has built a global presence with operations in North America, Europe, Asia and emerging markets. The company employs a research-driven model, investing heavily in clinical development and regulatory approvals to address unmet medical needs in viral and oncology therapeutics.

Gilead’s core business activities center on antiviral therapies, particularly for HIV and hepatitis C. Flagship products include Biktarvy and Descovy for HIV prevention and treatment, and Sovaldi and Harvoni for hepatitis C. In response to the COVID-19 pandemic, Gilead secured emergency use authorization for Veklury (remdesivir), an antiviral treatment that has been administered globally. Beyond antivirals, the company is expanding into oncology and inflammatory diseases, with cell therapy products such as Yescarta and Tecartus, which leverage CAR T technology to target specific cancers.

Over the years, Gilead has pursued strategic acquisitions and partnerships to bolster its pipeline. Notable transactions include the acquisition of Pharmasset in 2011, which fueled its hepatitis C franchise, and the purchase of Kite Pharma in 2017, establishing a foothold in cell therapy. The company supports a broad R&D network with centers in the U.S., Europe and Asia, collaborating with academic institutions, biotech firms and global health organizations to accelerate innovation.

Leadership at Gilead is guided by CEO Daniel O’Day, who joined the company in 2019 and brings experience from global healthcare organizations. Under his direction, Gilead has emphasized scientific rigor, operational efficiency and patient access initiatives. The company’s diverse executive team and board of directors maintain a strategic focus on sustainable growth, ethical conduct and advancing therapies that improve patient outcomes worldwide.

AI Generated. May Contain Errors.

Gilead Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
96th Percentile Overall Score

GILD MarketRank™: 

Gilead Sciences scored higher than 96% of companies evaluated by MarketBeat, and ranked 44th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Gilead Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 15 buy ratings, 9 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Gilead Sciences has only been the subject of 4 research reports in the past 90 days.

  • Read more about Gilead Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Gilead Sciences are expected to grow by 2.01% in the coming year, from $7.95 to $8.11 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Gilead Sciences is 23.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.00.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Gilead Sciences is 23.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.15.

  • Price to Earnings Growth Ratio

    Gilead Sciences has a PEG Ratio of 0.72. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Gilead Sciences has a P/B Ratio of 7.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Gilead Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    1.85% of the float of Gilead Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Gilead Sciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Gilead Sciences has recently increased by 9.79%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Gilead Sciences pays a meaningful dividend of 2.86%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Gilead Sciences has been increasing its dividend for 10 years.

  • Dividend Coverage

    The dividend payout ratio of Gilead Sciences is 66.53%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 38.96% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.

  • Read more about Gilead Sciences' dividend.
  • Percentage of Shares Shorted

    1.85% of the float of Gilead Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Gilead Sciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Gilead Sciences has recently increased by 9.79%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Gilead Sciences has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 48 news articles for Gilead Sciences this week, compared to 33 articles on an average week.
  • Search Interest

    92 people have searched for GILD on MarketBeat in the last 30 days. This is an increase of 163% compared to the previous 30 days.
  • MarketBeat Follows

    Only 21 people have added Gilead Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Gilead Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,236,245.00 in company stock.

  • Percentage Held by Insiders

    Only 0.27% of the stock of Gilead Sciences is held by insiders.

  • Percentage Held by Institutions

    83.67% of the stock of Gilead Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Gilead Sciences' insider trading history.
Receive GILD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.

GILD Stock News Headlines

Why Is President Trump Fast-Tracking These Companies?
Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His administration has begun to fast-track the operations of a handful of companies… Accelerating their potential profits.
See More Headlines

GILD Stock Analysis - Frequently Asked Questions

Gilead Sciences' stock was trading at $92.37 at the start of the year. Since then, GILD stock has increased by 19.8% and is now trading at $110.67.
View the best growth stocks for 2025 here
.

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings data on Thursday, April, 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences's revenue was down .3% on a year-over-year basis.
Read the conference call transcript
.

Gilead Sciences subsidiaries include these companies: MYR, Immunomedics, Forty Seven, Cell Design Labs, Kite Pharma, Nimbus Apollo, Epitherapeutics, and others.

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gilead Sciences investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Corning (GLW), NextEra Energy (NEE) and American Tower (AMT).

Company Calendar

Last Earnings
4/24/2025
Record date for 6/27 Dividend
6/13/2025
Ex-Dividend for 6/27 Dividend
6/13/2025
Dividend Payable
6/27/2025
Today
6/29/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GILD
Employees
17,600
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$110.55
High Stock Price Target
$140.00
Low Stock Price Target
$90.00
Potential Upside/Downside
-0.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
27 Analysts

Profitability

Trailing P/E Ratio
23.30
Forward P/E Ratio
13.92
P/E Growth
0.72
Net Income
$480 million
Pretax Margin
23.75%

Debt

Sales & Book Value

Annual Sales
$28.75 billion
Cash Flow
$6.87 per share
Price / Cash Flow
16.11
Book Value
$15.44 per share
Price / Book
7.17

Miscellaneous

Outstanding Shares
1,243,930,000
Free Float
1,240,570,000
Market Cap
$137.67 billion
Optionable
Optionable
Beta
0.29

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:GILD) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners